PMN310 PRECISE-AD is a ProMIS Neurosciences Inc. program in mild cognitive impairment due to AD or mild AD. Its next catalyst is a Readout in Q1 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Mild cognitive impairment due to AD or mild AD. Sponsor: ProMIS Neurosciences Inc. (PMN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for PMN310 PRECISE-AD is a Readout in Q1 2027.
No FDA decision for PMN310 PRECISE-AD is in our archive yet.
In our records PMN310 PRECISE-AD is under review or in development for Mild cognitive impairment due to AD or mild AD.
ProMIS Neurosciences Inc. (PMN).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.